Media

Press Releases

Spinogenix Announces FDA Clearance of IND Application for SPG302, a Novel Therapy for the Treatment of ALS

Spinogenix Announces U.S. FDA Orphan Drug Designation Granted to SPG601 for the Treatment of Fragile X Syndrome

Spinogenix Announces U.S. FDA Approval of its Investigational New DrugApplication for its Phase 2a Clinical Trial of SPG601 for Fragile X Syndrome

Spinogenix Announces Second Grant Award from U.S. Department of Defense to Further Advance SPG302, the First Synaptic Regenerative Drug to Treat Amyotrophic Lateral Sclerosis (ALS)

Spinogenix Awarded $3 Million NIH Grant to Support Continued Development of SPG302, the First Synaptic Regenerative Therapeutic for Alzheimer’s Disease

Spinogenix Receives Approval from the Australia Human Research Ethics Committee to Initiate a Phase 1 Human Clinical Trial of SPG302, a Novel Regenerative Drug for the Treatment of Amyotrophic Lateral Sclerosis (ALS)

Spinogenix Granted FDA Orphan Drug Designation for SPG302 for the Treatment of Amyotrophic Lateral Sclerosis

Spinogenix Announces Grant by U.S. Department of Defense to Advance Novel Drug Candidate in Amyotrophic Lateral Sclerosis (ALS)

In the News

FDA grants orphan designation to Fragile X syndrome therapeutic

Spinogenix’s SPG601 Earns Orphan Drug Designation for Fragile X Syndrome

FDA clears investigational new drug application for Fragile X treatment

Two major breakthroughs in Fragile X Syndrome treatments

Spinogenix’s Investigational New Drug Application for Novel Treatment for Fragile X Syndrome Cleared to Begin Phase II Trial

A Promising Treatment for MND

A new drug that could reverse the worst symptoms of MND is about to be trialled in Australia.

Novel motor neurone disease, MND, drug SPG302 to be trialled in Australia

ALS ONE Research Symposium – Presentation by Peter Vanderklish, PhD of Spinogenix

Spinogenix Lands $4M in New Federal Grants

Spinogenix awarded $1M to advance clinical testing of SPG302

Spinogenix: World-first trial giving hope to those living with MND

Clinical trial of oral ALS therapy SPG302 is enrolling in Australia | ALS News Today

Human Trial Gives Hope to MND Patients

Australians with MND will be the first in the world to trial a new drug

World first drug trial for MND treatment | Sky News Australia

A world-first trial for a new drug that may slow the progression of motor neurone disease is set to begin in Melbourne.

World first drug trial for MND treatment | The Australian

World first drug trial for MND treatment